Autoantibodies against tumor-associated antigens as one class of serological markers
https://doi.org/10.17650/2313-805X-2019-6-1-10-17
Abstract
This review is devoted to modern notions about autoantibodies (AAb) as one of classes of tumor biomarkers. Principles of humoral response by way of autoantibodies to different tumor-associated proteins in the process of malignant tumor progression are considered. During carcinogenesis self-proteins may become overexpressed, mutant, undergo posttranslational modification, localize abnormally, degrade aberrantly, becoming immunogenic and, as a result, be recognized by immune system as allogeneic. Advantages of AAb as biomarkers over its ligands – tumor antigens – are discussed.
Data regarding a diagnostic value of some AAb are given, modern methods of its assessment are considered. Possibilities of AAb using in screening, aimed at active diagnostics of cancer on early stages as well asAbout the Authors
N. V. Marshutina
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
Russian Federation
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284.
N. S. Sergeeva
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia.
Russian Federation
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284; 1 Ostrovityanova St., Moscow 117997.
I. I. Alentov
3 2nd Botkinskiy Proezd, Moscow 125284.
Russian Federation
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
Russian Federation
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
A. D. Kaprin
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
Russian Federation
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284.
References
1. Pedersen J.W., Wandall H.H. Autoantibodies as biomarkers in cancer. Labmedicine 2011;42(10):623—8. DOI: 10.1309/LM2T3OU3RZRTHKSN.
2. Tan H.T., Low J., Lim S.G., Chung M.C. Serum autoantibodies as biomarkers for early cancer detection. FEBS J 2009; 276(23):6880—904. DOI: 10.1111/j.1742-4658.2009.07396.x. PMID: 19860826
3. Macdonald I.K., Parsy-Kowalska C.B., Chapman C.J. Autoantibodies: opportunities for early cancer detection. Trends Cancer 2017;3(3):198—213. DOI: 10.1016/j.trecan.2017.02.003. PMID: 28718432.
4. Fortner R.T., Damms-Machado A., Kaaks R. Systematic review: tumor-associated antigen autoantibodies and ovarian cancer early detection. Gynecol Oncol 2017;147(2):465—80. DOI: 10.1016/j.ygyno.2017.07.138. PMID: 28800944.
5. Zhong L., Coe S.P., Stromberg A.J. et al. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol 2006;1(6):513—9. DOI: 10.1097/01243894-200607000-00003. PMID: 17409910.
6. Xu Y.W., Peng Y.H., Chen B. et al. Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma. Am J Gastroenterol 2014;109(1):36—45. DOI: 10.1038/ajg.2013.384. PMID: 24296751.
7. Bassaro L., Russell S.J., Pastwa E. et al. Screening for multiple autoantibodies in plasma of patients with breast cancer. Cancer Genom Proteom 2017;14(6):427—35. DOI: 10.21873/cgp.20052. PMID: 29109092.
8. Anderson K.S., Cramer D.W., Sibani S. et al. Autoantibody signature for the serologic detection of ovarian cancer. J Proteom Res 2015;14(1):578—86. DOI: 10.1021/pr500908n. PMID: 25365139.
9. Sergeeva N.S., Marshutina N.V., Solokhina M.P. et al. Modern conceptions of serological tumor markers and their role in oncology. Uspekhimolekulyarnoy onkologii = Advances in Molecular Oncology 2014;1(1):69—80. (In Russ.).
10. Moore R.G., Miller M.C., Disilvestro P. et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol 2011;118(2 Pt 1):280-8. DOI: 10.1097/AOG.0b013e318224fce2. PMID: 21775843.
11. Lu K.H., Skates S., Hernandez M.A. et al. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm(ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer 2013;119(19):3454—61. DOI: 10.1002/cncr.28183. PMID: 23983047.
12. Kaprin A.D., Alekseev B.Ya., Sergeeva N.S. et al. Clinical staging laboratory index is a new multiparameter indicator for prostate cancer. Onkologiya. Zhurnal imeni P.A. Gertsena = P.A. Herzen Journal of Oncology 2016;5(1):23—30. (In Russ.).
13. Sergeeva N.S., Skachkova T.E., Alekseev B.Ya. et al. APHIG: a new multiparameter index for prostate cancer. 2 Onkourologiya = Cancer Urology 2016;12(4):89—95. (In Russ.).
14. Zaenker P., Gray E.S., Ziman M.R. Autoantibody production in cancer — the humoral immune response toward autologous antigens in cancer patients. Autoimmun Rev 2016;15(5):477—83. DOI: 10.1016/j.autrev.2016.01.017. PMID: 26827909.
15. Zhang H.F., Qin J.J., Ren P.F. et al. A panel of autoantibodies against multiple tumor-associated antigens in the immunodiagnosis of esophageal squamous cell cancer. Cancer Immunol Immunother 2016;65(10):1233—42. DOI: 10.1007/s00262-016-1886-6. PMID: 27553002.
16. Murray A., Chapman C.J., Healey G. et al. Technical validation of an auto-antibody test for lung cancer. Ann Oncol 2010;21(8):1687—93. DOI: 10.1093/annonc/mdp606. PMID: 20124350.
17. Anderson K.S., Wong J., Vitonis A. et al. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Cancer Epidl Biomarkers Prev 2010;19(3):859—68. DOI: 10.1158/1055-9965.EPI-09-0880. PMID: 20200435.
18. Caron M., Choquet-Kastylevsky G., Joubert-Caron R. Cancer immunomics: using autoantibody signatures for biomarker discovery. Mol Cell Proteomics 2007;6(7):1115—22. DOI: 10.1074/mcp.r600016-mcp200. PMID: 17376768.
19. Qiu J., Keyser B., Lin Z.T. et al. Autoantibodies as potential biomarkers in breast cancer. Biosensors (Basel) 2018;8(3):E67. DOI: 10.3390/bios8030067. PMID: 30011807.
20. Chatterjee M., Mohapatra S., Ionan A. et al. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res 2006;66(2):1181 —90. DOI: 10.1158/0008-5472.can-04-2962. PMID: 16424057.
21. Houghton A.N., Gold J.S., Blachere N.E. Immunity against cancer: lessons learned from melanoma. Curr Opin Immunol 2001;13(2):134—40. DOI: 10.1016/s0952-7915(00)00195-3. PMID: 11228404.
22. Berezhnaya N.M., Chekhun V.F. Immunology of tumor growth. Project “Scientific book”. National Academy of Sciences of Ukraine. R.E. Kravetsky Institute of experimental pathology, oncology and radiobiology. Kiev: Naukova dumka, 2005. 792 p.(InRuss.).
23. Stevenson B.J., Iseli C., Panji S. et al. Rapid evolution of cancer/testis genes on the X chromosome. BMC Genomics 2007;8:129-39. DOI: 10.1186/1471-2164-8-129. PMID: 17521433.
24. Chatterjee M., Tainsky M.A. Non-traditional immunogens and their application to immunotherapy. Curr Opin Mol Ther 2008;10(1):62-7. PMID: 18228183.
25. Hanash S. Harnessing immunity for cancer marker discovery. Nat Biotechnol 2003;21(1):37—8. DOI: 10.1038/nbt0103-37. PMID: 12511908.
26. Suzuki H., Graziano D.F., McKolanis J. et al. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res 2005;11(4):1521—6. DOI: 10.1158/1078-0432.ccr-04-0538. PMID: 15746055.
27. Nesterova M., Johnson N., Cheadle C. et al. Autoantibody biomarker opens a new gateway for cancer diagnosis. Biochim Biophys Acta 2006;1762(4):398—403. DOI: 10.1016/j.bbadis.2005.12.010. PMID: 16483750.
28. Scanlan M.J., Chen Y.T., W'illiamson B. et al. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 1998;76(5):652—8. DOI: 10.1002/(sici)1097-0215(19980529)76:5<652::aidijc7>3.0.co;2-p. PMID: 9610721.
29. Fernandez Madrid F. Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. Cancer Lett 2005;230(2):187—98. DOI: 10.1016/j.canlet.2004.12.017. PMID: 16297705.
30. Coronella-Wood J.A., Hersh E.M. Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother 2003;52(12):715—38. DOI: 10.1007/s00262-003-0409-4. PMID: 16297705.
31. Li Z. Role of heat shock protein in chaperoning tumor antigens and modulating anti-tumor immunity. Chapter In Book: Tumor Antigens Recognized by T Cells and Antibodies. Eds.: H. Stauss, Y. Kawakami, G. Parmiani. Taylor and Francis, NY, 2003. Pp. 20—33.
32. Villanueva J., Shaffer D.R., Philip J. et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006;116(1):271—84. DOI: 10.1016/j.eururo.2006.02.005. PMID: 16395409.
33. Heo C.K., Bahk Y.Y., Cho E.W Tumor-associated autoantibodies as diagnostic and prognostic biomarkers. BMB Reports 2012;45(12):677—85. DOI: 10.5483/BMBRep.2012.45.12.236. PMID: 23261052.
34. Xu Y.W., Liu C.T., Huang X.Y. et al. Serum Autoantibodies against STIP1 as a potential biomarker in the diagnosis of esophageal squamous cell carcinoma. Disease Markers 2017;2017:5384091. DOI: 10.1155/2017/5384091.PMID: 28852266.
35. Scanlan M.J., Gordan J.D., W'illiamson B. et al. Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer 1999;83(4): 456—64. DOI: 10.1002/(sici)1097-0215(19991112)83:4<456::aidijc4>3.3.co;2-x. PMID: 10508479.
36. Cho H., Kim S., Shin H.Y. et al. Expression of stress-induced phosphoprotein1 (STIP1) is associated with tumor progression and poor prognosis in epithelial ovarian cancer. Genes Chromosomes Cancer 2014;53(4):277—88. DOI: 10.1002/gcc.22136. PMID: 10508479.
37. Chao A., Lai C.H., Tsai C.L. et al. Tumor stress-induced phosphoprotein1 (STIP1) as a prognostic biomarker in ovarian cancer. PLoS One 2013;8(2):e57084. DOI: 10.1371/journal.pone.0057084. PMID: 23468915.
38. Chapman C.J. Healey G.F., Murray A. et al. EarlyCDT® Lung test: improved clinical utility through additional autoantibody assays. Tumour Biology 2012;33(5):1319—26. DOI: 10.1007/s13277-012-0379-2. PMID: 22492236.
39. Sullivan F.M., Farmer E., Mair F.S. et al. Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test(ECLS): study protocol for a randomized controlled trial. BMC Cancer 2017;17(1):187—97. DOI: 10.1186/s12885-017-3175-y. PMID: 28284200.
40. Jett J.R., Healey G., Macdonald I. et al. Determination of the detection lead time for autoantibody markers in early stage lung cancer using the UKCTOCS cohort. J Thorac Oncol 2017;12(No.11S2):S2170.
41. Mathew J., Healey G., Jewell W. et al. Demographics of populations at high risk of lung cancer and results of the Early CDT-Lung test. J Clin Oncol 2010;28(15):7033. DOI: 10.1200/jco.2010.28.15_suppl.7033.
42. Edelsberg J., Weycker D., Atwood M. et al. Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules. PLoS One 2018;13(5):e0197826. DOI: 10.1371/journal.pone.0197826. PMID: 29787590.
43. Anderson K.S., Sibani S., Wallstrom G. et al. Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res 2011;10(1):85—96. DOI: 10.1021/pr100686b. PMID: 20977275.
44. Liu Y., Liao Y., Xiang L. et al. A panel of autoantibodies as potential early diagnostic serum biomarkers in patients with breast cancer. Int J Clin Oncol 2017;22(2):291—6. DOI: 10.1007/s10147-016-1047-0. PMID: 27778118.
Review
For citations:
Marshutina N.V., Sergeeva N.S., Alentov I.I., Kaprin A.D. Autoantibodies against tumor-associated antigens as one class of serological markers. Advances in Molecular Oncology. 2019;6(1):10-17. (In Russ.) https://doi.org/10.17650/2313-805X-2019-6-1-10-17
Views:
804
Email this article 